Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.

Bleeding risk lower with rivaroxaban vs warfarin for nonvalvular atrial fibrillation

17 Oct 2019

Rivaroxaban leads to less major bleeding than warfarin when used to treat nonvalvular atrial fibrillation in patients with stage 4 or 5 chronic kidney disease, a recent study has found.

The study included 1,896 rivaroxaban (median age, 72 years; 41.6 percent female) and 4,848 warfarin (median age, 72 years; 38.4 percent female) users, who were followed until the occurrence of stroke/systemic embolism, major bleeding event or discontinuation/switching of medication. Patient groups were matched based on propensity scores. Participants were eligible if they had nonvalvular atrial fibrillation and had stage 4/5 chronic kidney disease or undergoing haemodialysis.

Patients who took rivaroxaban showed a 32-percent less likelihood of developing major bleeding complications relative to their warfarin counterparts (hazard ratio [HR], 0.68, 95 percent CI, 0.47–0.99).

This was driven mostly by between-treatment differences in the risk of intracranial (HR, 0.19, 0.02–1.56) and gastrointestinal (HR, 0.87, 0.58–1.30) bleeding, though neither subtype achieved significance on its own.

The risks of ischaemic stroke (HR, 0.67, 0.30–1.50) or stroke/systemic embolism (HR, 0.55, 0.27–1.10) remained comparable between those who were treated with rivaroxaban and warfarin.

“Despite guideline recommendations, rivaroxaban is used in patients with nonvalvular atrial fibrillation and stage 4 or 5 chronic kidney disease and among those receiving haemodialysis,” said researchers. The present findings revealed that there may not be serious ramifications to this practice.

However, researchers pointed out that “[a]dditional studies are needed to confirm the effectiveness and safety of rivaroxaban in patients with severe kidney dysfunction and to help determine optimal dosing in this population.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.